THE JOHN R. LEE, M.D. MEDICAL LETTER (March 2002)
PROSTATE DISEASE AND HORMONES
The solutions are straightforward when you understand the problem.
If you know a man over the age of 50 who's not sleeping well, chances are good
it's because he's got prostate problems that require visits to the bathroom a
couple of times a night. It's estimated that benign prostate disease affects over
40 percent of American men by age 50 and over 70 percent by age 60. The most common
symptom is trouble with urination. Such men may have urinary frequency (hence
getting up at night), their urine flow may be decreased in force or rate, they
may have urinary urgency, and they may feel that they haven't emptied the bladder
(a sign of urinary retention), especially after drinking coffee. Urinary retention
also makes them more susceptible to urinary tract infections.
When such men consult with their doctor, he will usually examine the prostate
gland through the rectum (a digital exam) and diagnose the problem as BPH, an
acronym meaning benign prostate hypertrophy (enlarged cells in the prostate gland)
or hyperplasia (enlarged by an increase in the number of cells in the gland).
The two meanings of BPH are used interchangeably. BPH, like most conditions, varies
in how it manifests itself. In some men, the obstruction of urine flow is due
to prostate tissue overgrowth and the gland will be definitely enlarged. In others,
however, the obstruction is due to smooth muscle contraction of the urinary sphincters
in the prostate gland, causing the same urinary problems without much prostate
enlargement. In some men, the problem is mixed.
Conventional Medicines for the Prostate
The doctor may prescribe the drug terazosin (Hytrin) to relax urinary sphincter
muscles, or the drug finasteride (Proscar) which inhibits the enzyme 5 alpha reductase,
which converts testosterone into dihydrotestosterone (DHT, a compound believed
to stimulate prostate cell growth, or hyperplasia). Or, he may recommend transurethral
resection of the prostate (TURP), the surgical coring out of the urine passageway
through the prostate, quite often resulting in undesirable dribbling problems.
The success rate of the two drugs listed above is not uniform or consistent. Both
drugs were tested in an interesting study in the New England Journal of Medicine
(NEJM) in 1996. It was found that finasteride (the hyperplasia inhibitor) helped
men with considerable prostate gland enlargement, but not those with more normal
sized prostate glands. Interestingly, saw palmetto berry and nettle root similarly
inhibit 5alpha reductase, and are just as effective as finasteride. Though often
beneficial in BPH, neither saw palmetto berry nor finasteride prevent prostate
cancer.
Terazosin (the smooth muscle relaxer) helped men with less gland enlargement,
but not men with larger prostate glands. None of these treatments recognize the
true importance of sex hormones that underlie the cause of BPH.
The Role of Sex Hormones
Conventional medicine is beginning to recognize the true role of sex hormones
in prostate disease. For example, like a woman, a man's body fat will convert
male hormones into estrogen. Some physicians advocate using aromatase inhibiting
drugs (such as Arimidex) that inhibit the conversion of adrenalgenerated androstenedione
(a male hormone) into estrone (an estrogen) in body fat. Estrone is then available
to be converted to estradiol. The rationale for this treatment is the understanding
that estrogen is a growth stimulating hormone in prostate tissue. This leads us
to the hypothesis that the balance of estradiol to progesterone and/or to testosterone
is an important factor in prostate disease.
As men age, prostate levels of estradiol gradually rise, and levels of progesterone
and testosterone decline. The decline in testosterone and progesterone levels
is greater than the rise of estradiol. The ratio of testosterone to estradiol
MEA for instance, is dramatically lower in men over 60 than it is at age 40. Studies
in the U.S., Germany and Japan have reached similar conclusions: not only is the
T/E2 ratio lower in men after age 40, but also those men with the lowest T/E2
ratio are the ones most likely to develop BPH. Conventional medicine, stuck in
the outdated and unfounded paradigm that claims testosterone is dangerous, opts
to attack and destroy estrogen production rather than supplement testosterone
in their effort to raise the T/E2 ratio and protect men against prostate disease.
Why not raise the low testosterone levels by supplementing physiological doses
of testosterone to restore the ratio of T/E2 to that of younger men? There is
no evidence that the high levels of testosterone in young men puts them at any
risk of BPH. Or of prostate cancer, for that matter.
Progesterone's Role
Progesterone plays several roles in the protection against prostate disease. Progesterone,
like finasteride and saw the conversion of testosterone to DHT. In this manner,
progesterone helps raise testosterone levels, and helps lower the level of the
more growth stimulating DHT. Progesterone, like testosterone, is an anabolic hormone,
meaning that it helps burn fat for energy. Thus, it helps keep men from becoming
obese. With less body fat, there is less endogenous (within the body) estrone
production. Further, both progesterone and testosterone stimulate gene p53, the
product of which protects us from the oncogene (cancer causing) Bcl 2, and stimulates
healthy apoptosis (normal cell death). Estradiol, on the other hand, stimulates
Bcl 2 production, which increases the risk of cancer. These are all good reasons
to restore the same progesterone and testosterone levels that younger men have.
Restoring Hormone Balance
Restoring proper hormone levels is not difficult. The best place to begin is with
a saliva hormone test, so that you have clinical evidence of a hormone imbalance.
Saliva hormone testing reflects the total blood levels of non protein bound ("free")
sex hormones. The free hormone is bioavailable and filters into saliva, whereas
the protein bound (non bioavailable) hormones do not. Conventional blood serum
tests of estradiol, for example, are essentially irrelevant since they do not
distinguish between free and protein bound estradiol. I usually recommend ZRT
Lab in Oregon; you can order a kit through their Web site www.salivatest. com,
or you can call them at (503) 466 2445. You do not need a doctor's prescription
to get a saliva hormone test, although I do recommend that you work with a qualified
health professional to help interpret the results.
The ratio of saliva progesterone to estradiol in healthy young men is usually
greater than 200: 1. Similarly, the ratio of saliva testosterone to estradiol
is also about 200 to 300: 1. These ratios can be used as a guideline for the transdermal
supplementation of progesterone and testosterone in older men with E2 dominance
and low P/E2 and T/E2 ratios. From experience, we have found that just 6 to 8
mg per day of progesterone (in a cream) will raise low saliva progesterone levels
to normal healthy levels. In a two ounce jar or tube of cream containing 960 mg
of progesterone, this would be a bit less than 1/8 tsp of cream daily, and it
would last for about 140 days, or about four and a half months.
Testosterone, being a stronger hormone, usually requires just I to 2 mg per day
by transdermal cream to raise low levels to healthy normal levels. Creams with
the proper testosterone content are not readily available, so a patient with BPH
should ask his doctor to write a prescription for the cream, then take it to a
compounding pharmacist. It is essential that the pharmacist use real testosterone,
and not one of the synthetic versions such as methyltestosterone.
I have seen remarkable benefits and no side effects in men who use hormones this
way. The low doses used attest to the excellent absorption of these hormones when
applied transdermally. As an interesting aside, in a recent study of women with
low free testosterone levels (in women after removal of their ovaries), the researchers
found that the optimal dose of transdermal testosterone for them was just 0.25
mg per day.
Defense Against Prostate Cancer
Research has shown that BPH is not a risk factor for prostate cancer. Nevertheless,
defense against prostate cancer follows the same precepts. Men with aggressive
prostate cancer have higher numbers of progesterone receptors (PRs), relative
to men with less aggressive cancer. This does not mean that progesterone increases
the aggressiveness of prostate cancer. Progesterone receptors are made only by
estrogen. An increase of PRs in prostate tissue is a sign of estradiol dominance
(relative progesterone deficiency). In other studies it is found that prostate
cancer incidence is greater in men with lower T/E2 ratios (lower testosterone
and higher E2 levels) than in men with higher T/E2 ratios.
Conventional medicine's fear of testosterone is unfounded. In clinics that routinely
treat men with even higher doses of testosterone, the incidence of prostate cancer
is usually less than in men without supplemental testosterone. While it is true
that, in 19 4 1, Dr. Huggins claimed to have demonstrated that castration (removal
of testes) in men with prostate cancer delayed death (a bit) from their cancer,
it does not mean that testosterone reduction was the cause of this observed benefit.
Dr. Huggins forgot that the testes also supply estrogen. It is far more likely
that the estrogen reduction was the source of the benefit. Since that time, it
is now clear that total androgen blockade does not enhance longevity compared
to men without total androgen blockade. It is time to recognize that progesterone
and testosterone are important hormones in men, and that normal physiological
levels of these hormones do not increase the risk of prostate cancer but, on the
other hand, may help prevent prostate cancer.
Some research indicates that BPH and prostate cancer correlate with higher levels
of sex hormone binding globulin (SHBG). As a result, some have hypothesized that
SHBG may play a role in the cause of BPH and of prostate cancer. SHBG is the binding
hormone for estradiol. Excessive levels of estradiol activate the liver to make
more SHBG. Thus, it is likely that the elevated SHBG is merely a marker for excessive
estradiol. Observations are one thing, but the conclusions that one draws from
them are quite something else. Conclusions often follow underlying assumptions
that may be erroneous, and are subject to observer bias.
Xenoestrogen (petrochemical toxins often used as pesticides, etc.) exposure during
embryo life may damage gonadal and prostate tissue, making these tissues more
susceptible to carcinogens later in life. Although one can't change these circumstances,
one can take preventive steps to reduce estrogen levels and maintain hormone balance.
Our new book, What Your Doctor May Not Tell You About Breast Cancer, goes into
some detail about how to avoid xenoestrogens.
Some Non Drug Treatments for BPH
Certain botanicals have been found to be of benefit in treating prostate disease
though their mechanisms of action are still unclear. These botanicals, and a few
others like them, deserve further research. Many products for the prostate found
at health food stores contain various combinations of these ingredients.
" " Saw Palmetto berry extract, according to Jonathan Wright, M.D.,
not only inhibits 5alpha reductase but also blocks DHT binding to prostatic androgen
receptors, reduces prostatic edema (swelling), inhibits estradiol and antagonizes
alpha adrenergic receptors.
" " Nettle root (may inhibit aromatase, reducing conversion of androgens
to estrogen).
" " Antioxidants, such as vitamin E, lycopene (found in cooked tomatoes),
and vitan An C.
" " Polyphenols (e.g., catechins, found in green tea.)
" " Ellagic acid (found in nuts and raspberries) may trigger beneficial
apoptosis.
" " Zinc (low zinc levels correlate with increased prostate disease).
Be sure to get extra copper if you're taking zinc for longer than a few weeks.